Apex BiotechnologyTPE:1733 -0.17%81 PE Ratio without NRI is 17.18 as of Jul. 08, 2026, which is 18% below its 10-year median of 21.03. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 265 Biotechnology companies, Apex Biotechnology ranks better than 66.04% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-08), Apex Biotechnology's share price is NT$29.90.
Apex Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.74. Therefore, Apex Biotechnology's PE Ratio without NRI for today is 17.18.
During the past 13 years, Apex Biotechnology's highest PE Ratio without NRI was 45.56. The lowest was 10.65. And the median was 21.03.
Apex Biotechnology's EPS (Basic) for the
three
months ended in Dec. 2025 was NT$0.50.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.63.
Apex Biotechnology (TPE:1733) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Apex Biotechnology PE Ratio without NRI Related Terms
Apex Biotechnology PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison
For the Biotechnology subindustry, Apex Biotechnology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's PE Ratio without NRI falls into.
Apex Biotechnology PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Apex Biotechnology's Share Price of today is NT$29.90.
Apex Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Apex Biotechnology (TPE:1733) has a PE Ratio without NRI of 17.18 as of Jul. 08, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Apex Biotechnology and its competitors. This is 18% below median its historical median of 21.03. Over the past decade, Apex Biotechnology's PE Ratio without NRI has ranged from 10.65 to 45.56. According to the industry distribution chart, Apex Biotechnology ranks #90 out of 265 companies in the Biotechnology industry, placing it in the top 34%.
Is Apex Biotechnology's PE Ratio without NRI too high?
Apex Biotechnology's current PE Ratio without NRI of 17.18 is 18% below median its 10-year median of 21.03. Over the past 10 years, this metric has ranged from a low of 10.65 to a high of 45.56. The Biotechnology industry median PE Ratio without NRI is 25.30. Apex Biotechnology's value of 17.18 is 32.1% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #90 out of 265 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #90 out of 265 companies for PE Ratio without NRI. This puts Apex Biotechnology in the upper half of its industry. The industry median PE Ratio without NRI is 25.30. Apex Biotechnology's value of 17.18 is 32.1% below this benchmark. Historically, Apex Biotechnology's own PE Ratio without NRI has ranged from 10.65 to 45.56 over the past decade. While the company's 10-year median is 21.03 vs. the industry median of 25.30, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.30, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current PE Ratio without NRI of 17.18 is 32.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current PE Ratio without NRI is 17.18, which is 18% below median its own 10-year median of 21.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current PE Ratio without NRI is 17.18, which is 18% below median its 10-year median of 21.03 and 32.1% below the Biotechnology industry median of 25.30. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current PE Ratio without NRI is 17.18 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
PE Ratio without NRI: 17.18 (18% below median its 10-year median of 21.03)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 32.1% below the Biotechnology median (#90 of 265)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
